ISRCTN16102051已完成Unknown
Introduction of a Head and Neck Cancer General Practitioner communication pathway in Community Pharmacies in NHS Tayside (CP HNC GP Communication Pathway)
HS Tayside0 个研究点目标入组 30 人开始时间: 2023年4月26日最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Any adult (age 18 years+), registered with a GP in Dundee City, who presents to one of the participating pharmacies with relevant symptoms as outlined in the protocol
- •2. Participating community pharmacists
- •3. GPs/clinicians who review patient participant(s)
排除标准
- •1. People without symptoms meeting study criteria
- •2. People not registered with a GP in Dundee City
- •2. Non-consenting individuals
- •3. Any person under the age of 18 years
- •4. Any person unable to participate in a consultation conducted in the English language
研究者
相似试验
进行中（未招募）
不适用
What are my options? A feasibility study of a personalized primary prevention strategy for women and men at high risk of breast and prostate cancerBreast and prostate cancersCancerISRCTN15749766CHU de Québec-Université Laval120
招募中
不适用
A Phase I, first-in-human, multicenter, open-label, dose escalation followed by an expansion phase clinical study of KBA1412 given as monotherapy or in combination with pembrolizumab in adults with advanced solid malignant tumorsmelanomaSolid Tumors10018865NL-OMON53468Kling Biotherapeutics B.V.22
已完成
不适用
A phase 1, first-in-human, multicenter, open-label, dose-escalation study to characterize the safety and tolerability of MP0317 in patients with relapsed/refractory advanced solid tumorsNL-OMON51895Molecular Partners AG30
尚未招募
不适用
The CorNeat EverPatch is a First-In-Human clinical study aimed at demonstrating the safety of a synthetic tissue substitute for covering a glaucoma tube shunt.Eye DiseasesSurgeryPACTR202007844168087CorNeat Vision Ltd15
终止
1 期
A Study To Determine The Safety, Tolerability, Pharmacokinetics And Recommended Phase 2 Dose Of CCX559 In patients With Solid Tumorseoplastic Disorder - Solid TumorsNeoplastic Disorder - Solid TumorsCancer - Any cancerACTRN12621001342808ChemoCentryx, Inc21